TY - JOUR AU - Rashighi, Mehdi AU - Harris, John E. PY - 2015 TI - Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo JF - Annals of Translational Medicine; Vol 3, No 21 (December 17, 2015): Annals of Translational Medicine Y2 - 2015 KW - N2 - Vitiligo is a common, disfiguring autoimmune disease caused by the destruction of epidermal melanocytes. It presents with patchy depigmentation of skin, which significantly affects patients’ self-esteem and quality of life. The mainstay of vitiligo treatment is topical steroids, calcineurin inhibitors, and/or narrow band UVB (nbUVB) phototherapy ( 1 ). These treatments utilize a non-targeted approach with moderate efficacy, but are used off-label, as they are not Food and Drug Administration (FDA)-approved for use in vitiligo. Currently, the only FDA-approved treatment for the disease is monobenzone cream (Benoquin ® ), which is actually used to permanently depigment, rather than repigment, the skin. This treatment results in an even skin tone, and can be appropriate for patients with extensive disease ( 2 , 3 ). However, it is one of a limited number of treatments used in medicine to intentionally make disease worse, and treatments focused on reversing vitiligo, with better efficacy, are greatly needed. UR - https://atm.amegroups.org/article/view/8589